{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:37:48Z","timestamp":1792701468850,"version":"4.5.0"},"reference-count":13,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV\n                      <jats:sub>1<\/jats:sub>\n                      in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though the latter correlates better with poor asthma control and type 2 inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>21 GINA-defined severe asthma patients who were treated with benralizumab and who had baseline oscillometry-defined SAD were included in this study. Here, SAD was diagnosed only if patients satisfied both R5\u2013R20\u22650.10 kPa\/L\/s and AX\u22651.0 kPa\/L. The mean duration of follow-up between pre-benralizumab versus post-benralizumab clinical measurements was 8 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean values for FEV\n                      <jats:sub>1<\/jats:sub>\n                      % and FVC% but not FEF\n                      <jats:sub>25%\u201375%<\/jats:sub>\n                      significantly increased following benralizumab, along with significant reductions in Asthma Control Questionnaire (ACQ). There were no significant improvements in R5\u2013R20, X5 or AX, while the mean (SEM) PBE count fell to 23 (14) cells\/\u00b5L. In a responder analysis, n=8\/21 and n=12\/21 patients experienced improvements exceeding biological variability of 0.04 kPa\/L\/s and 0.39 kPa\/L in R5\u2013R20 and AX, respectively, in severe asthma. N=10\/21, n=10\/21 and n=11\/21 patients experienced improvements in FEV\n                      <jats:sub>1<\/jats:sub>\n                      , FEF\n                      <jats:sub>25\u201375<\/jats:sub>\n                      and FVC exceeding biological variability of 150 mL, 0.210 L\/s and 150 mL, respectively. In contrast, n=15\/21 patients experienced an improvement in ACQ greater than minimal clinical important difference of 0.5 units.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eosinophil depletion with benralizumab improves spirometry and asthma control but does not improve spirometry-measured or oscillometry-measured SAD in severe asthma in a real-life setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001472","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T08:00:24Z","timestamp":1684483224000},"page":"e001472","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma"],"prefix":"10.1136","volume":"10","author":[{"given":"Rory","family":"Chan","sequence":"first","affiliation":[{"name":"Scottish Centre for Respiratory Research, University of Dundee School of Medicine, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J","family":"Lipworth","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Research, University of Dundee School of Medicine, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"2025083112173763000_10.1.e001472.1","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.jaip.2020.06.048","article-title":"Pragmatic clinical perspective on Biologics for severe refractory type 2 asthma","volume":"8","author":"Chan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083112173763000_10.1.e001472.2","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.jaip.2020.07.031","article-title":"Impulse Oscillometry Bronchodilator response and asthma control","volume":"8","author":"Kuo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083112173763000_10.1.e001472.3","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1111\/all.14339","article-title":"Oscillometry improves earlier than Spirometry after Benralizumab initiation in severe asthma","volume":"75","author":"Shirai","year":"2020","journal-title":"Allergy"},{"key":"2025083112173763000_10.1.e001472.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01679-2021","article-title":"Repeatability of impulse Oscillometry in patients with severe asthma","volume":"59","author":"Chan","year":"2022","journal-title":"Eur Respir J"},{"key":"2025083112173763000_10.1.e001472.5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1164\/rccm.201812-2322OC","article-title":"Lung computational models and the role of the small Airways in asthma","volume":"200","author":"Foy","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083112173763000_10.1.e001472.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00543-2022","article-title":"Interactions between Spirometry and Oscillometry in patients with moderate to severe asthma","volume":"60","author":"Chan","year":"2022","journal-title":"Eur Respir J"},{"key":"2025083112173763000_10.1.e001472.7","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14a06.x"},{"key":"2025083112173763000_10.1.e001472.8","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d29.x"},{"key":"2025083112173763000_10.1.e001472.9","doi-asserted-by":"crossref","first-page":"110444","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-life effects of Benralizumab on exacerbation number and lung Hyperinflation in Atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2025083112173763000_10.1.e001472.10","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00329.2007"},{"key":"2025083112173763000_10.1.e001472.11","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic Rhinosinusitis with nasal polyps: A real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083112173763000_10.1.e001472.12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MCP.0000000000000018","article-title":"The role of small airway disease in asthma","volume":"20","author":"Bjermer","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"2025083112173763000_10.1.e001472.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00082314"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:17:45Z","timestamp":1756667865000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,19]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjresp-2022-001472"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001472","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}